Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rare flowers atop the patent cliff: Sanofi picks itself up

This article was originally published in Scrip

Executive Summary

Nobody expected 2012 to be a great year for Sanofi: the global number two pharma company has had to grapple with the loss of market exclusivity in key markets for major brands including the blood thinners Lovenox (enoxaparin) and Plavix (clopidogrel), the antihypertensive Aprovel (irbesartan), the chemotherapeutic Taxotere (docetaxel) and most recently Eloxatin (oxaliplatin). However, the advent of generic competition to Eloxatin in the US in August marked the end of Sanofi's patent cliff for now. And it looks likely that actually, 2012 won't be quite as bad as was once feared.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020305

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel